To date, 22 patients have been described as harboring pathogenic variations in IGF1R in the HGMD. We found that patients with compound heterozygous or homozygous variations displayed more severe phenotypes that were mainly characterized by developmental and speech delays, as well as mental retardation.
Conclusion:
We identified four pathogenic variations in the IGF1R gene, which expanded the known mutation spectrum. Through a comparison among patients with reported IGF1R pathogenic variations, this study determined that an autosomal-recessive inheritance model of the IGF1R gene may result in a more severe phenotype with developmental and speech delays, as well as mental retardation. (J Clin Endocrinol Metab 103: 3939-3944, 2018) I GF and its receptor play an important role in prenatal brain development that is independent of their role in GH signaling. IGF-1 receptor (IGF1R) deficiency (Online Mendelian Inheritance in Man #270450) causes intrauterine growth retardation or postnatal growth retardation, with the possibility of microcephaly and intellectual disability (1) . Both autosomal-dominant and autosomal-recessive inheritance have been reported (2) . IGF1R deficiency has been observed in a few families with biallelic IGF1R pathogenic variants (1, 3) .
In this study, we analyzed the IGF1R gene in children with growth impairment using whole-exome sequencing (WES) and assessed the clinical features of the autosomaldominant and autosomal-recessive models.
Methods

Study population
Patients were enrolled between 1 January 2016 and 31 December 2016 who were suspected of prenatal and postnatal growth failure and met two of the following four criteria: (1) prenatal growth failure, small for gestational age (SGA), defined as a birth weight (BW) less than the third percentile (P 3 ) for gestational age (GA) (4); (2) postnatal growth failure defined as weight and length less than 22 SDs below the normal mean for age and sex (5); (3) microcephaly defined as head circumference less than 22 SDs for age and sex (5); and (4) development delay or speech delay (Wechsler Intelligence Scale for Children-III).
Patients were excluded if they had been diagnosed with metabolic disorders or genetic disorders, and the pathogenic copy number variants were identified using array-based comparative genomic hybridization.
The samples used in this study were collected with appropriate informed consent and the approval of the ethics committee of the Children's Hospital of Fudan University. The methods used in this study were carried out in accordance with the approved guidelines.
WES
Genomic DNA fragments of patients were enriched for exome sequences using the Agilent Technologies SureSelectXT Human All Exon 50 Mb kit (Santa Clara, CA). The DNA fragments were ligated with adaptors, and two paired-end DNA libraries with insert sizes of 500 bp were formed for all samples. The DNA libraries after enrichment by PCR were sequenced on the HiSeq2000/2500 sequencer according to the manufacturer's instructions (Illumina, San Diego, CA), resulting in 90-bp paired-end sequencing reads with at least 100-fold average sequencing depth for each sample.
Variants with suboptimal quality scores were removed from consideration. The remaining variants were annotated by ANNOVAR and Variant Effect Predictor software and compared computationally with the list of reported mutations from the Human Gene Mutation Database (HGMD; professional version). The variants also identified in the HGMD were retained. Among the changes that were not in the HGMD, synonymous variants, intronic variants that were .15 bp from exon boundaries (which are unlikely to affect mRNA splicing), and common variants (minor allele frequency .1%) were also discarded. Missense variants were assessed with SIFT, Polymorphism Phenotyping v2 (PolyPhen-2), and MutationTaster.
Confirmation and in silico assays
The detected variants were confirmed using PCR, and the PCR-amplified DNA products were subjected to direct automated sequencing (3500XL Genetic Analyzer; Thermo Fisher Scientific, Waltham, MA) according to the manufacturer's specifications.
In silico tools were applied to identify the potential functional impacts of the newly identified variants. These variants were assessed in silico using online tools such as the sequence homology-based tool SIFT, PolyPhen-2 (http://genetics. bwh.harvard.edu/pph2), and MutationTaster (http://www. mutationtaster.org/). We downloaded the FASTA sequence for the IGF1R gene from the National Center for Biotechnology Information, selected the specific region harboring the variants as a protein structure template, and performed automated modeling for this region (https://www.swissmodel. expasy.org). The resultant protein structures were visualized by PyMOL 1.7.4.
Statistical tests
The clinical features of our cases carrying IGF1R variants and the patients with IGF1R pathogenic variations reported in the HGMD were compared. Differences in the occurrence of developmental delay in different mutation type groups were analyzed using Fisher exact test. A two-sided P value was used to test for statistical significance (P , 0.05).
Results
We identified four variants in the IGF1R gene in three unrelated patients by WES.
The mother of patient 1 was gravida 2 para 1, and patient 1 was GA 38 weeks, BW 2.34 kg, and SGA with no catch-up in linear growth. At the age of 2 years 1 month, her height was 74.5 cm (23.85 SDs), her weight was 8.5 kg (23.20 SDs), and her body mass index (BMI) was 15.3 (20.5 SD). Her bone age was 1.5 years. The pedigree of patient 1 is shown in Fig. 1A . Her mother has short stature (height 150 cm; 21.96 SDs), and her father's height (173 cm; 0.05 SDs) is normal. She received GH stimulation and an IGF-1 test. The basal level of GH was 6.94 ng/mL. The GH provocative test was performed via the intravenous infusion of arginine (0.5 g/kg) and the insulin hypoglycemia method, and the GH peak level was 17.3 ng/mL (normal value $10.0 ng/mL). The basal serum IGF-1 concentration was 102 ng/mL, which was normal (6) . GH treatment (0.3 mg/kg/week) was started when the patient was 2 years 10 months of age. However, she did not respond well to GH, and her height velocity changed from less than 23 SD to less than 22 SD at 8 years of age (Fig. 1B) . Her mental development is normal. We identified one missense variant [exon 21: c.3740T.C, (p.M1247T)] in this patient, which she inherited from her affected mother. Her father carried the wild type of this variant. This variant is absent from the Exome Aggregation Consortium (ExAC), the 1000 Genomes database, and our internal database including 12,101 sets of WES data and 22,308 sets of medical exome-sequencing data. This variant was predicted to be deleterious by SIFT and MutationTaster. The threedimensional (3D) structure showed how the variant affects the structure of the protein (Fig. 2B) . Combined, the phenotype and molecular analyses suggest that this variation in the IGF1R gene is a likely pathogenic variant.
Patient 2 was a girl, GA 38 weeks, BW 1.85 kg, and SGA. At the age of 10 years 8 months, her height was 125 cm (22.44 SDs), weight was 29 kg (20.66 SDs), BMI was 18.6 (0.5 SD), and head circumference was 48.4 cm (22.52 SDs). Her mother's height (160 cm; 20.11 SDs) is normal, and her father (158 cm; 22.41 SDs) has short stature. The basal level of GH was 0.36 ng/mL, and the GH peak level was 15.4 ng/mL (normal value $10.0 ng/mL). The basal serum IGF-1 concentration was 509 ng/mL, the normal range is 51 to 303 ng/mL. We identified a missense variant [exon3: c.744T.G (p.C248W)] in this patient (Fig. 2) , which she inherited from her affected father. This variant is absent from ExAC, the 1000 Genomes database, dbSNP, and our internal database. This variant was predicted to be deleterious by SIFT, PolyPhen-2, and MutationTaster. The 3D structure showed how the variant affects the structure of the protein (Fig. 2B) . Therefore, we identified this variant as a likely pathogenic variant.
Patient 3 was a full-term boy, BW 3.45 kg, and appropriate GA (25th to 50th percentile). However, at the age of 4 years, his height was 94 cm (22. Fig. 2A  and 2B ). Both variants were validated by Sanger sequencing on a 3500XL instrument (Thermo Fisher Scientific). R895Q and E769Q are paternal and maternal variants, respectively. These two variants are absent from ExAC, the 1000 Genomes database, and our internal database. Both variants are predicted to be deleterious by MutationTaster. The 3D structure showed that the E769Q variant affects the structure of the protein. We identified the two variants as likely pathogenic variants.
To date, 22 patients have been described as harboring pathogenic variations in IGF1R in the HGMD (as of February 2017). The clinical descriptions of our cases carrying IGF1R variants and the other reported patients with IGF1R pathogenic variations are shown in Table 1 ( 1-3, 8, 11, 15, 18, 21) . Out of the 25 cases (we identified 3 new cases and reviewed 22 previously reported cases), 4 displayed the recessive model, and 21 exhibited the dominant model. All cases with homozygous or compound heterozygous variants suffered from development delay, and only 7 out of 21 cases with heterozygous variants had development delay. Patients exhibiting the recessive model displayed a more severe phenotype, characterized by developmental and speech delays and mental retardations, than those with the dominant model (P = 0.0261).
Discussion
In this study, we enrolled 28 patients with prenatal or postnatal growth failure, and we identified four variants in the IGF1R gene by WES in three of these unrelated patients. These four variants have not been reported before. Our study expanded the mutation database of the IGF1R gene.
To date, 22 patients have been described as harboring pathogenic variations in IGF1R in the HGMD. In our study, delayed motor development and speech delay were observed in patient 3, who had compound heterozygous variants. An additional three patients have been described as carrying homozygous or compound heterozygous variants of the IGF1R gene in the HGMD. Our patient 3 had compound heterozygous variants, Prontera et al. (3) reported a homozygous variant (c.2201G.T) , In reviewing the previously reported cases, we found that the clinical phenotypes, in addition to postnatal growth retardation, were variable, including elevated IGF-1 levels and intrauterine growth retardation that were not consistently observed among all reported cases (22) . Patient 3 was appropriate GA at birth and gradually showed short stature; at the age of 4 years, his height was 22.61 SDs. Patient 1 has severely short stature with missense variant p.M1247T inherited from her mother. Her mother's height is on the borderline of what is considered abnormally short. The phenotypic heterogeneity, which can be observed even within a family, suggests variability in the degree of loss of IGF1R function and/or the involvement of other genetic factors in influencing the development of the pathological features seen in these patients.
In summary, we identified four pathogenic variations of the IGF1R gene, which expanded the mutation spectrum. We compared our cases with the patients with IGF1R pathogenic variations reported in the HGMD. This study demonstrates that the autosomal-recessive inheritance model of the IGF1R gene results in severe developmental delays and mental retardation. 
